Search results for " Breast Cancer"

showing 10 items of 427 documents

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

2021

A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m2 on day 1 and 8, plus capecitabine 1000 mg/m2 bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentVinorelbineCapecitabineStable DiseaseInternal medicineCarcinomamedicinebreast carcinomaoral chemotherapymetastasesChemotherapybusiness.industrycapecitabinemedicine.diseaseMetastatic breast cancervinorelbineSettore MED/18 - Chirurgia GeneraleToxicitybusinessBreast carcinomaBiotechnologymedicine.drugResearch Article
researchProduct

Adjuvant denosumab in early breast-cancer

2020

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).

Oncologymedicine.medical_specialtyadjuvant denosumab early-stage breast cancerBone Density Conservation AgentsAromatase Inhibitorsbusiness.industrymedicine.medical_treatmentMEDLINEantiresorptives denosumab breast cancer osteonecrosis od the jawosteonecrosis od the jawdenosumabantiresorptivesBone Density Conservation Agentsbreast cancerDenosumabOncologyInternal medicineMedicinebusinessAdjuvantmedicine.drugEarly breast cancerThe Lancet Oncology
researchProduct

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approac…

2014

Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. Th…

Oncologymedicine.medical_specialtybiologybusiness.industryCyclin-dependent kinase 4Settore MED/06 - Oncologia MedicaInhibitor proteinBiochemistryEpigenetic therapy NF-κB inhibition Raf-1 kinase inhibitor protein triple-negative breast cancersInternal medicineRaf 1 kinaseGeneticsbiology.proteinCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineMedicineIdentification (biology)businessTriple negativeEpigenetic therapyBiotechnology
researchProduct

13P Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)

2021

Oncologymedicine.medical_specialtybiologybusiness.industryScoring methodsHematologyLigand (biochemistry)OncologyInternal medicinePD-L1biology.proteinComparison studyMedicinebusinessTriple-negative breast cancerProgrammed deathAnnals of Oncology
researchProduct

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA).

1993

Oncologymedicine.medical_specialtybusiness.industryGeneral NeuroscienceEndocrine therapyBreast Neoplasmsmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPostmenopauseTamoxifenBreast cancerHistory and Philosophy of SciencePremenopauseReceptors EstrogenChemotherapy AdjuvantRecurrenceInternal medicinemedicineCooperative groupHumansFemalebusinessEarly breast cancerProbability
researchProduct

Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 n…

2018

Oncologymedicine.medical_specialtybusiness.industryHER2 negativeRibociclibHematologymedicine.diseaseMetastatic breast cancerOncologyHormone receptorInternal medicinemedicineFirst line chemotherapybusinessHormoneAnnals of Oncology
researchProduct

Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results …

2017

Oncologymedicine.medical_specialtybusiness.industryInternal medicineAdvanced breastmedicineCancerSurgeryGeneral Medicinebusinessmedicine.diseaseMetronomic ChemotherapyMetronomic Chemotherapy Advanced Breast Cancer
researchProduct

Plasmatic Plasminogen Activator Inhibitor Activity in Patients with Primary Breast Cancer

1997

Oncologymedicine.medical_specialtybusiness.industryInternal medicineMedicineIn patientHematologyPrimary breast cancerProspective cohort studybusinessPlasminogen activatorThrombosis and Haemostasis
researchProduct

Patient Reported Outcome in metastatic breast cancer and platinum-resistant recurrent ovarian cancer treated with metronomic cyclophosphamide ± metho…

2021

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseaseMetastatic breast cancerRecurrent Ovarian CancerInternal medicineMedicinePatient-reported outcomeMethotrexatebusinessMetronomic cyclophosphamidePlatinum resistantmedicine.drugSenologie - Zeitschrift für Mammadiagnostik und -therapie
researchProduct

A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastat…

2018

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseasePlaceboMetastatic breast cancerlaw.inventionCapecitabine03 medical and health sciences0302 clinical medicineRandomized controlled triallawTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusiness030217 neurology & neurosurgerymedicine.drugGeburtshilfe und Frauenheilkunde
researchProduct